Market Newsdesk

iHeartMedia Unveils the Next-Generation iHeartRadio App

Delivers industry-first features and a fresh, tailored user experience based directly on listener feedback

NEW YORK–(BUSINESS WIRE)–
iHeartMedia, the No. 1 audio company in America by reach, today announced the debut of its next-generation iHeartRadio app, redesigned with industry-first mobile features and access to exclusive content. The new app interface — iHeartRadio’s most significant product update since its initial launch in 2011 — embraces the ease and simplicity that listeners want and have come to expect with broadcast radio in the car — bridging the gap between the traditional car radio experience and mobile streaming. Drawing from extensive user research and feedback, the redesigned iHeartRadio app reflects iHeartMedia’s commitment to delivering a seamless and simplified radio listening experience tailored to the express needs of a modern audience using all the technology tools available today.

iHeart reaches more consumers in America than any other media, and that day-to-day relationship with hundreds of millions of listeners in the U.S. provides the unique insights and feedback used in developing this next-generation app experience.

“Our listeners have made it clear that they want a streaming audio platform that’s intuitive and familiar, reflecting the simplicity of the car radio while embracing the full capabilities of streaming technology,” said Bob Pittman, Chairman and CEO of iHeartMedia, Inc. “The redesigned iHeartRadio app does just that, bringing together the best features of the car radio and the mobile app. We are excited to offer this new and improved iHeartRadio app just in time for Christmas – it’s our special gift to our listeners.”

The updated iHeartRadio app design combines all the features of the car radio that listeners know and love with innovative digital technology enhancements, including:

1. Presets: In an audio-industry first and drawing inspiration directly from the car dashboard, custom presets allow listeners to save up to 15 of their favorite radio stations, playlists, podcasts and artist radio stations — the ones they love listening to the most and come back to most often. The presets will be available throughout the app.
2. Scan Button: In another audio-industry first, listeners can discover new stations with scan, and seamlessly sample nationwide radio stations, or filter by city or genre. It’s a brand-new way for app users to navigate iHeartRadio’s unparalleled broadcast radio dial, ensuring their new favorite stations are never out of reach – and they can discover new ones that they’ll love.
3. Live Radio Dial: This new app feature enables listeners to easily explore the best live stations across the country. This experience mimics the same car radio experience that listeners know and love, but has the added benefit of being organized by genre and location for ease of discovery.
4. What’s Trending Rankers: Users will have access to an innovative discovery feature that allows them to see what’s trending at that moment among other listeners across Top Podcasts, Top Playlists and Top Artist Radio stations, as well as features that are trending on iHeartRadio.

5. Lyrics: The most requested new listener feature, iHeart is now the only digital radio app to offer lyrics for the song users are listening to on live radio. Users will also be able to follow lyrics karaoke style for tracks on artist radio and playlists.

In addition to these new features, exclusive editorial content produced by iHeartMedia stations across the country is now accessible from inside the iHeartRadio app. It’s the ultimate artist fan hub with the latest news about the biggest artists, all of iHeartRadio’s exclusive in-studio interviews and the one-tap, enter-to-win contests that iHeart is so famous for that fans can now easily explore inside the app while listening to their favorite music and podcasts.

“The new iHeartRadio app further underscores iHeartMedia’s mission to use the power of audio to build companionship and connection,” said Conal Byrne, CEO of the iHeart Digital Audio Group. “This experience blends the familiarity of the car radio with digital innovation to enable users to easily find the stations, artists and podcasts they know and love, fostering the fun, spontaneous discovery and connection that comes with live car radio – all through their phones, anywhere they go.”

Initial rollout of the new iHeartRadio app begins today and will be available to all listeners on Android and iOS by December 17. Download the iHeartRadio app today from the App Store or Google Play to explore the next era of digital listening.

About iHeartMedia, Inc.

iHeartMedia, Inc. [Nasdaq: IHRT] is the leading audio media company in America, with 90% of Americans listening to iHeart broadcast radio in every month. iHeart’s broadcast radio assets alone have a larger audience in the U.S. than any other media outlet; twice the size of the next largest broadcast radio company; and over four times the ad-enabled audience of the largest digital only audio service. iHeart is the largest podcast publisher according to Podtrac, with more downloads than the next two podcast publishers combined, has the most recognizable live events across all genres of music, has the number one social footprint among audio players, with seven times more followers than the next audio media brand, and is the only fully integrated audio ad tech solution across broadcast, streaming and podcasts. The company continues to leverage its strong audience connection and unparalleled consumer reach to build new platforms, products and services. Visit iHeartMedia.com for more company information.

View source version on businesswire.com: https://www.businesswire.com/news/home/20241212043206/en/

Media Contact:

Angel Aristone

[email protected]

Jenn Powers

[email protected]

KEYWORDS: New York United States North America

INDUSTRY KEYWORDS: Entertainment Apps/Applications Technology TV and Radio General Entertainment Music Podcast

MEDIA:

Logo

SentinelOne Recognized as a 2024 Gartner® Peer Insights™ Customers’ Choice forManaged Detection and Response

95% of end users expressed willingness to recommend SentinelOne’s MDR services

MOUNTAIN VIEW, Calif.–(BUSINESS WIRE)–SentinelOne® (NYSE: S), a global leader in AI-powered security, today announced that it has been named a Customers’ Choice in the recently released Gartner® Peer Insights™ ‘Voice of the Customer: Managed Detection and Response Services’ report. More than 210 users provided reviews of SentinelOne’s Managed Detection and Response (MDR) services, and 95 percent expressed a willingness to recommend them.

A Foundation for World-Class Cyberdefense

Built on SentinelOne’s AI-powered Singularity™ Platform, a Gartner Peer-Insights Customer Choice for endpoint protection platforms, SentinelOne Vigilance MDR and Singularity MDR harness the power of SentinelOne’s industry-trusted threat experts and intelligence to provide enhanced detection and response coverage, empowering security teams to scale and strengthen their cyberdefense.

According to an IT Security and Risk Management Associate at an IT services company, SentinelOne provides “A proactive and powerful service designed to enhance the organisation’s cybersecurity through continuous monitoring, threat hunting, and incident response. It performs exceptionally well by combining advanced technology with expert human oversight and also ensuring robust protection against cyber threats.”

And as described by the head of IT for a consumer goods company, “Sentinel One is the best MDR I have ever seen, this solution has many features like shorter Mean Time to Respond (MTTR), a complete solution, backed up with AI, 24x7x365 coverage and many more. A proactive approach towards response, detection and protection is one of the key features which makes this product top of others. Deep analysis, threat insights and the mitigation process are among the best of their kind. I also liked the reporting dashboard where I am getting a complete incident report with threat analysis.”

The Gartner Peer Insights Customers’ Choice recognition comes on the heels of SentinelOne being positioned as a leader in the 2024 Gartner Magic Quadrant for Endpoint Protection Platforms for a second consecutive year and achieving a perfect score in the 2024 MITRE ATT&CK Evaluations: Enterprise. SentinelOne was also named a CRN 2024 Product of the Year.

“The threat landscape is rapidly and constantly evolving, and to future-proof their cybersecurity, organizations need round-the-clock coverage, tailored to their environment to keep their operations secure,” said Warwick Webb, Vice President, Managed Detection and Response, “SentinelOne’s MDR Services combine AI-powered technology with the expertise of seasoned practitioners delivering effective protection and true peace of mind.”

To learn more about SentinelOne’s MDR Services and the value they can deliver, click here.

About Gartner Peer Insights Customer’s Choice

The Gartner Peer Insights Customers’ Choice recognizes vendors in this market based on reviews from verified end-user professionals. The Customers’ Choice distinction takes into account both the number of reviews and the overall user ratings. To ensure fair evaluation, Gartner maintains rigorous criteria for recognizing vendors with a high customer satisfaction rate.

GARTNER is a registered trademark and service mark of Gartner, Inc. and/or its affiliates in the U.S. and internationally, MAGIC QUADRANT and PEER INSIGHTS are registered trademarks of Gartner, Inc. and/or its affiliates and is used herein with permission. All rights reserved.

Gartner Peer Insights content consists of the opinions of individual end users based on their own experiences with the vendors listed on the platform, should not be construed as statements of fact, nor do they represent the views of Gartner or its affiliates. Gartner does not endorse any vendor, product or service depicted in this content nor makes any warranties, expressed or implied, with respect to this content, about its accuracy or completeness, including any warranties of merchantability or fitness for a particular purpose.

Gartner does not endorse any vendor, product or service depicted in its research publications, and does not advise technology users to select only those vendors with the highest ratings or other designation. Gartner research publications consist of the opinions of Gartner’s research organization and should not be construed as statements of fact. Gartner disclaims all warranties, expressed or implied, with respect to this research, including any warranties of merchantability or fitness for a particular purpose.

About SentinelOne

SentinelOne is a leading AI-powered cybersecurity platform. Built on the first unified Data Lake, SentinelOne empowers the world to run securely by creating intelligent, data-driven systems that think for themselves, stay ahead of complexity and risk, and evolve on their own. Leading organizations—including Fortune 10, Fortune 500, and Global 2000 companies, as well as prominent governments – trust SentinelOne to Secure Tomorrow™. Learn more at sentinelone.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20241212674186/en/

Media Contact:

Karen Master

[email protected]

KEYWORDS: California United States North America

INDUSTRY KEYWORDS: Data Management Security Technology Software Artificial Intelligence Internet

MEDIA:

Logo

JetBlue Opens Crew Base in San Juan, Bringing More than 400 Jobs to Puerto Rico by Next Year

JetBlue adds even more service and low fares for customers in “La Isla del Encanto” with new flights from San Juan to St. Croix taking off today

SAN JUAN, Puerto Rico–(BUSINESS WIRE)–
JetBlue (Nasdaq: JBLU), Puerto Rico’s largest carrier, today celebrated the opening of its brand-new crew base at San Juan’s Luis Muñoz Marín International Airport (SJU) – its first outside the continental U.S., bringing hundreds of jobs with it. The celebration and growth continue this afternoon, as JetBlue also marks the start of flights from Puerto Rico’s vibrant capital to the stunning island of St. Croix in the U.S. Virgin Islands, further solidifying its investment in the Caribbean.

JetBlue’s newly opened San Juan crew base is set to bring more than 400 crewmember jobs to Puerto Rico, with more than 100 pilots and more than 300 inflight crewmembers (flight attendants) set to be assigned to the base by next year. The crew base to support inflight crewmembers opened today while San Juan-based pilots are expected to join in early 2025. Located in Terminal A at San Juan’s airport, the base will allow crewmembers to begin and end trips from the island, supporting the airline’s operations in Puerto Rico, the Caribbean, and beyond and ensure these workgroups can quickly respond in the event of operational disruptions. The crew base follows the opening of JetBlue’s Tech Ops maintenance base in San Juan in 2020.

“We are proud to celebrate this important milestone in Puerto Rico,” said Warren Christie, chief operating officer at JetBlue. “The new crew base reinforces our commitment to investing in the communities we serve, creating opportunities for crewmembers in San Juan and for those who want to return home to the island, while expanding our network to meet the growing demand for travel to the Caribbean and beyond.”

“We celebrate that JetBlue continues to bet on Puerto Rico. We are proud of this strategic alliance with Puerto Rico, reinforcing the airline’s commitment to the island and its people. Our tourism had record growth numbers over the past four years, and this is one more sign that good news continue for our people,” said Puerto Rico Governor Pedro R. Pierluisi.

“Providing reliable and affordable travel options to customers is a key part of the development of the tourism sector and we are very excited to be part of this new phase of JetBlue’s history in Puerto Rico. The opening of this crew base confirms the airline’s commitment to Puerto Rico, and enhances both the increase in frequency of flights to all the airports of the island, as well as new opportunities to continue expanding the network from domestic and international markets that benefit the local economy,” said Carlos Mercado Santiago, executive director of the Puerto Rico Tourism Company.

JetBlue has been serving Puerto Rico for more than 22 years and flies to 18 destinations from the island. With over 50 daily departures in peak periods this winter, JetBlue’s recent network growth has created an additional 70 new jobs, bringing its team to more than 800 crewmembers by 2025 across San Juan, Aguadilla, and Ponce.

New flights from San Juan to St. Croix take off today

To add to JetBlue’s growth in Puerto Rico, today the airline will celebrate its inaugural flight from San Juan to St. Croix. Part of the U.S. Virgin Islands, St. Croix blends vibrant culture and natural beauty. Visitors will experience historic sites, lush gardens, and charming streets, or unwind on pristine beaches like Protestant Cay or Rainbow Beach. With a thriving art scene and diverse adventures, St. Croix stands out as a relaxing Caribbean escape.

“We are excited to reenter St. Croix, known for its rich history, stunning beaches, and great people,” said Christie. “Our new route between San Juan and St. Croix demonstrates our commitment to serving the Caribbean and connecting U.S. Virgin Islands residents to our San Juan focus city as well as the robust network we serve beyond it.”

St. Croix joins St. Thomas in the U.S. Virgin Islands as part of JetBlue’s network. The airline currently offers daily service between San Juan and St. Thomas as well as winter seasonal flights between Boston and St. Thomas.

“Today’s flight, traveling just over 94 miles, provides depth in the connectivity of St. Croix to not just Puerto Rico but to the broader Caribbean region and the mainland United States,” shares Commissioner Joseph Boschulte of the U.S. Virgin Islands Department of Tourism. “We are excited for the continued growth of our relationship with JetBlue and look forward to welcoming more passengers.”

JetBlue’s relaunch of service to St. Croix is part of JetBlue’s significant network enhancements in San Juan and focus on leisure and VFR (visiting friend and relatives) routes, aligned with the airline’s JetForward strategy.

Schedule between San Juan (SJU) and St. Croix (STX)

SJU-STX Flight #2940	STX-SJU Flight #2941
3:00 p.m. – 3:44 p.m.	4:45 p.m. – 5:35 p.m.

JetBlue will operate the St. Croix route using its Airbus A320 aircraft, offering the airline’s award-winning service featuring fast, free and unlimited broadband Fly-Fi¹; complimentary name-brand snacks and drinks; and seatback entertainment at every seat.

To celebrate today’s launch, and for a limited time, travelers can take advantage of special $29 one-way fares for flights to and from San Juan to St. Croix available online only on jetblue.com².

Customers who book directly through jetblue.com are guaranteed to find JetBlue’s lowest fares, and can enjoy additional benefits including access to all of the airline’s fare options, as well as fare sales and promotions, some of which may not be available through other third parties; the ability to earn 2x TrueBlue points and participate in Points Pooling; seamless seat selections and upgrades to Even More^® Space; 24/7 direct access to JetBlue’s customer service channels; and more.

JetBlue is proud to offer flights between San Juan and Boston; Cancún, Mexico; Fort Lauderdale, Orlando and Tampa Fla.; Hartford, Conn.; Medellín, Colombia; Newark, N.J.; New York (JFK); Providence, R.I.; Raleigh/Durham, N.C.; St. Croix and St. Thomas, U.S.V.I.; Santiago, Punta Cana and Santo Domingo, Dominican Republic; Washington, D.C. (Reagan National); and Westchester County, N.Y.

About JetBlue

JetBlue is New York’s Hometown Airline^®, and a leading carrier in Boston, Fort Lauderdale-Hollywood, Los Angeles, Orlando and San Juan. JetBlue carries customers to more than 100 destinations throughout the United States, Latin America, Caribbean, Canada and Europe. For more information and the best fares, visit jetblue.com.

1. Fly-Fi^® and live television are available on all JetBlue-operated flights. Availability and coverage area may vary by aircraft. Details on inflight wi-fi and entertainment: https://www.jetblue.com/flying-with-us.

2. San Juan (SJU) to/from St. Croix (STX): One-way only. Book by: 12/13/2024 for travel 12/16/24 – 3/31/2025.

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20241212241628/en/

JetBlue Corporate Communications

Tel: +1.718.709.3089

[email protected]

KEYWORDS: Latin America Virgin Islands (U.S.) Caribbean Puerto Rico

INDUSTRY KEYWORDS: Air Transportation Transport Destinations Travel

MEDIA:

Posted on December 12, 2024 9:03 am

The Future for Restaurants is Bright (and Tech-Driven), TD Bank Survey Finds

The Future for Restaurants is Bright (and Tech-Driven), TD Bank Survey Finds

Following recent industry challenges, appetite for expansion and investment in mobile apps and artificial intelligence grows

CHERRY HILL, N.J.–(BUSINESS WIRE)–
The last five years have provided significant challenges to the restaurant franchise industry. However, the industry has renewed optimism, driven by the adoption of digital and mobile ordering, menu creativity and heightened expectations around AI. This is according to a survey conducted by TD Bank at the 2024 Restaurant Finance and Development Conference in Las Vegas, Nevada. The poll collected insights from 175 restaurant operators and financial professionals to uncover their expectations for 2025.

Continued technological advancements, better value meal strategies, as well as a better interest rate outlook are driving optimism. In fact, respondents believe lowering interest rates will have the greatest impact on the restaurant industry in the next 12 months (46%), followed closely by artificial intelligence and automation (42%). The industry’s addiction to value menus appears to be moderately paying off, with a slight majority of operators indicating that the associated increase in foot traffic (60%) offsets the margin compression from these programs (40%). Furthermore, more than half (52%) of respondents say they’ve seen improved underlying foot traffic trends as compared to just three months ago.

Franchise 2.0: Prioritizing Investments in Mobile Apps and Artificial Intelligence

Looking ahead, restaurant operators and financial professionals are focusing on investments that drive revenue and simplify operations – especially mobile apps. When asked about their predictions for the top three revenue drivers for restaurants over the next 12 months, more than three-fourths (77%) of respondents ranked mobile ordering number one. Similarly, 59% of respondents believe mobile apps that offer easy online ordering will have the greatest impact on operations over that same time period.

“The push for convenience and efficiency to improve customer and employee experiences is driving the industry’s focus on mobile ordering,” said Mark Wasilefsky, Head of Franchise Finance, TD Bank. “The continued focus on mobile apps and online ordering tools signals a demand to better accommodate changing consumer expectations and employee needs.”

Meeting these consumer expectations and employee needs is pushing restaurant franchises towards artificial intelligence and automation. The survey found 43% of respondents believe that using AI to analyze customer data and predict market shifts will have the greatest impact on operations, followed by the automation of admin tasks to let restaurant managers spend more time helping employees (34%).

Ultimately, mobile apps and automation are key growth areas over the next 12 months, with 36% of respondents predicting restaurants/franchises will invest in digital platforms, mobile apps and online ordering to enhance customer experience, as well as technology to automate and streamline operations.

2025: The Year of M&A Growth

As lowering interest rates and technological innovation boost optimism, restaurant franchise leaders are turning their attention to mergers and acquisitions. Over the next 12 months, 84% of respondents believe mergers and acquisitions (M&A) activity will increase.

“Restaurant franchising as an industry is gearing up for an exciting time, with improved profitability and a better interest rate outlook offsetting moderating traffic and portending a reemergence in dealmaking and franchise expansion,” said Wasilefsky. “Despite 2024’s challenges with foot traffic and AUVs, a few factors are coming together to bolster the outlook – including the careful application of value menus, confidence in technology from AI driven efficiencies and continual improvement in the digital experience. Together, they are creating an optimistic outlook for revenue, margins and overall industry performance.”

Survey Methodology

This study was conducted at the 2024 Restaurant Finance and Development Conference held in Las Vegas, Nevada from November 11-13, 2024. A total of 175 restaurant franchise operators and finance industry professionals were polled.

About TD Bank, America’s Most Convenient Bank^®

TD Bank, America’s Most Convenient Bank, is one of the 10 largest banks in the U.S. by assets, providing over 10 million customers with a full range of retail, small business and commercial banking products and services at more than 1,100 convenient locations throughout the Northeast, Mid-Atlantic, Metro D.C., the Carolinas and Florida. In addition, TD Auto Finance, a division of TD Bank, N.A., offers vehicle financing and dealer commercial services. TD Bank and its subsidiaries also offer customized private banking and wealth management services through TD Wealth^®. TD Bank is headquartered in Cherry Hill, N.J. To learn more, visit www.td.com/us. Find TD Bank on Facebook at www.facebook.com/TDBank and on Instagram at www.instagram.com/TDBank_US/.

TD Bank is a subsidiary of The Toronto-Dominion Bank, a top 10 North American bank. The Toronto-Dominion Bank trades on the New York and Toronto stock exchanges under the ticker symbol “TD”. To learn more, visit www.td.com/us.

View source version on businesswire.com: https://www.businesswire.com/news/home/20241212094383/en/

Media:

Nick Villano

TD Bank

Communications Manager

[email protected]

KEYWORDS: New Jersey United States North America

INDUSTRY KEYWORDS: Apps/Applications Technology Finance Banking Professional Services Restaurant/Bar Retail Artificial Intelligence Online Retail

MEDIA:

Logo

Williams-Sonoma, Inc. declares quarterly cash dividend

SAN FRANCISCO–(BUSINESS WIRE)–
Williams-Sonoma, Inc. (NYSE: WSM) announced today that its Board of Directors has declared a quarterly cash dividend of $0.57 per share of common stock. Each stockholder of record as of the close of business on January 17, 2025 will be paid the cash dividend on February 21, 2025.

ABOUT WILLIAMS-SONOMA, INC.

Williams-Sonoma, Inc. is the world’s largest digital-first, design-led and sustainable home retailer. The company’s products, representing distinct merchandise strategies — Williams Sonoma, Pottery Barn, Pottery Barn Kids, Pottery Barn Teen, West Elm, Williams Sonoma Home, Rejuvenation, Mark and Graham, and GreenRow — are marketed through e-commerce websites, direct-mail catalogs and retail stores. These brands are also part of The Key Rewards, our loyalty and credit card program that offers members exclusive benefits across the Williams-Sonoma family of brands. We operate in the U.S., Puerto Rico, Canada, Australia and the United Kingdom, offer international shipping to customers worldwide, and have unaffiliated franchisees that operate stores in the Middle East, the Philippines, Mexico, South Korea and India, as well as e-commerce websites in certain locations. We are also proud to be a leader in our industry with our values-based culture and commitment to achieving our sustainability goals. Our company is Good By Design — we’ve deeply ingrained sustainability into our business. From our factories to your home, we’re united in a shared purpose to care for our people and our planet.

For more information on our sustainability efforts, please visit: https://sustainability.williams-sonomainc.com/

WSM-DIV

View source version on businesswire.com: https://www.businesswire.com/news/home/20241212087274/en/

Jeff Howie

EVP, Chief Financial Officer

(415) 402-4324

-or-

Jeremy Brooks

SVP, Chief Accounting Officer

Investor Relations

(415) 733-2371

KEYWORDS: California United States North America

INDUSTRY KEYWORDS: Catalog Home Goods Online Retail Retail Specialty

MEDIA:

Posted on December 12, 2024 8:58 am

iTeos Therapeutics Presents Interim A2A-005 Clinical Trial Data, Translational, and Preclinical Data from Inupadenant at ESMO Immuno-Oncology Congress

– Inupadenant + carboplatin/pemetrexed in Phase 2 A2A-005 trial demonstrated a 63.9% overall response rate (ORR) and a median PFS of 7.7 months for all evaluable patients across the cohorts

– Recommended Phase 2 dose (RP2D) of inupadenant 80mg + carboplatin/pemetrexed demonstrated 73.3% ORR, with 64.6% of patients achieving landmark 6-month PFS

– Inupadenant + carboplatin/pemetrexed safety profile was manageable and tolerable, with no dose-dependent toxicity observed

– Inupadenant deprioritized to focus resources on other programs

WATERTOWN, Mass. and GOSSELIES, Belgium, Dec. 12, 2024 (GLOBE NEWSWIRE) — iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of immuno-oncology therapeutics for patients, today announced the presentation of clinical, translational, and preclinical data from its adenosine A_2A receptor (A_2AR) antagonist program, inupadenant, including interim data from the dose escalation portion of A2A-005, the Phase 2 trial assessing inupadenant and platinum-doublet chemotherapy in post-immunotherapy metastatic non-small cell lung cancer (NSCLC) patients, at the European Society for Medical Oncology Immuno-Oncology (ESMO IO) Congress 2024.

“We believe our presentations at ESMO IO on the adenosine pathway demonstrate the strong efforts our research and discovery team have put into understanding this immunosuppressive mechanism,” said Michel Detheux, Ph.D., president and chief executive officer of iTeos. “While the initial signal for inupadenant’s RP2D in the A2A-005 trial compared to chemotherapy alone is encouraging and supports its differentiated, insurmountable profile, we as well as our scientific and clinical advisory boards believe it does not meet sufficient level of clinical activity to warrant further investment. We remain committed to focusing our resources on developing differentiated, first- or best-in-class therapies and look forward to providing updates on our pipeline in 2025.”

Mini Oral Sessions

Title: Inupadenant Combined with Chemotherapy in Patients with Non-Squamous NSCLC Progressing On or After Immune Checkpoint Inhibitor Therapy: Results from Dose-Finding Part of the A2A-005 Trial
Summary: As of the October 29, 2024 data cutoff, the topline data from the dose escalation portion of A2A-005 presented at the ESMO IO Congress were based on 36 patients eligible for safety and efficacy evaluation. Patients received inupadenant at 40mg, 60mg, or 80mg twice daily (BID) in combination with carboplatin/pemetrexed. All patients had a minimum follow-up of 6 months. Patient baseline characteristics were balanced across arms, with a slight imbalance of more patients with brain metastases in the 40mg and 80mg cohorts and ECOG status 0 favoring the 80mg cohort.

• The primary endpoint of the safety of inupadenant in combination with carboplatin/pemetrexed was observed to be manageable and tolerable, with no dose dependent toxicities.
• The secondary endpoint of ORR was 63.9% across all patients (53.3% at 40mg, 66.7% at 60mg, and 73.3% at 80mg).
• The secondary endpoint of mPFS was 7.7 months across all patients (5.6 months at 40mg and 6.6 months at 60mg; mPFS remains unreached at 80mg).
• The exploratory biomarker of CXCL13, a B-cell chemokine and lymphoid structure marker associated with clinical activity, was observed to be restored by inupadenant after depletion by chemotherapy, with quicker restoration kinetics in patients with PFS greater than 6 months.
• As of the data cutoff, 8 patients remained on treatment (1 at 40mg, 1 at 60mg, and 6 at 80mg). The median follow-up was 9.7 months (10.6 months at 40mg, 13.1 months at 60mg, and 8.2 months at 80mg).

Response Measure	Inupadenant 40mg + carboplatin / pemetrexed BID		Inupadenant 60mg + carboplatin / pemetrexed BID		Inupadenant 80mg + carboplatin / pemetrexed BID		Overall
	(N=15)		(N=6)		(N=15)		(N=36)
ORR, %	53.3 %		66.7 %		73.3 %		63.9 %
n (95% CI)	n=8 (26.6–78.7)		n=6 (22.3–95.7)		n=15 (44.9–92.2)		n=36 (46.2–79.2)
Complete response, n (%)	0		0		2 (13.3%)		2 (5.6%)
Partial response, n (%)	8 (53.3%)		4 (66.7%)		9 (60.0%)		21 (58.3%)
Stable disease, n (%)	7 (46.7%)		1 (16.7%)		3 (20.0%)		11 (30.6%)
Progressive disease, n (%)	0		0		1 (6.7%)		1 (2.8%)
Not evaluable/no assessment, n (%)	0		1 (16.7%)		0		1 (2.8%)
mPFS, months	5.6		6.6		NC		7.7
Event n (%) (95% CI)	13 (86.7%) (4.1-8.3)		5 (83.3%) (0.4-NC)		6 (40.0%) (4.9-NC)		24 (66.7%) (5.1-11.0)
Landmark 6-Month PFS %	46.7% (21.2-68.7)		50.0% (11.1-80.4)		64.6% (34.7-83.5)		54.5% (36.8-69.1)

CI, confidence interval; NC, not calculable

Title: The A_2AR Antagonist Inupadenant Promotes Humoral Responses in Patients
Summary: Based on monotherapy clinical and translational data, inupadenant demonstrated modulation of humoral responses in patient blood and tumor tissue, supporting our previous finding that expression of antibody-secreting cells (ASCs) in tumor tissue is associated with non-progression in patient disease. Furthermore, CXCL13 expression, a protein involved in immune cell recruitment, activation, and adaptive immune response regulation, increased in patients treated with inupadenant and more rapidly and extensively in non-progressors compared to progressors. These findings confirm inupadenant plays a key role in B cell maturation restoration and may play a substantial role in delaying progression in end-stage patients.

Poster Sessions

Title: The A_2AR Antagonist Inupadenant Promotes Humoral Responses in Preclinical Models
Summary: In preclinical models, inupadenant counteracted the A_2AR-mediated inhibition of B cell maturation into ASCs and immunoglobulin production in both in vitro and ex vivo systems by modulating B cells at the level of the germinal center (GC). These findings suggest that inupadenant restores or even enhances B cell maturation towards ASCs and GC reactions in both secondary lymphoid organs as well as the tumor in the presence of A_2AR signaling. Furthermore, this process is essential for producing high-affinity antibodies and potentially for sustained anti-tumor immunity.

Title: A Novel Tumor Adenosine Signature to Guide Indication Selection for Adenosine Pathway inhibitor
Summary: Based on the spatial quantification of adenosine in human tumors, we developed the first adenosine gene signature, demonstrating its potential for indication selection. This new signature, derived from 249 differentially expressed genes (DEGs) associated with metabolism and immune activation, showed high predictive power across tumor types. Furthermore, the adenosine signature was higher in tumors compared to healthy tissue and exhibited variable expression and prognostic value across tumor subtypes. These findings suggest that the adenosine signature represents a powerful tool for prioritizing tumor types which may benefit most from adenosine-targeting therapies and for understanding the mechanisms of adenosine-mediated immunosuppression.

About iTeos Therapeutics, Inc.
iTeos Therapeutics is a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of immuno-oncology therapeutics for patients. iTeos Therapeutics leverages its deep understanding of tumor immunology and immunosuppressive pathways to design novel product candidates with the potential to restore the immune response against cancer. The Company’s innovative pipeline includes three clinical-stage programs targeting novel, validated immunosuppressive pathways designed with optimized pharmacologic properties for improved clinical outcomes, including the TIGIT/CD226 axis and the adenosine pathway. iTeos Therapeutics is headquartered in Watertown, MA with a research center in Gosselies, Belgium.

About Inupadenant (EOS-850)

Inupadenant is a next-generation small molecule antagonist targeting adenosine A_2A receptor (A_2AR), the primary receptor on immune cells whose activation by adenosine suppresses innate and adaptive immune cell responses leading to inhibition of antitumor responses. Optimized for potency, high selectivity of A_2AR, and activity at high adenosine concentrations in solid tumors, inupadenant is uniquely designed with its insurmountable profile to inhibit the ATP-adenosine pathway and has the potential for enhanced antitumor activity as compared to other A_2AR antagonists in clinical development. The therapeutic candidate is in Phase 2 development. 

Internet Posting of Information
iTeos routinely posts information that may be important to investors in the ‘Investors’ section of its website at www.iteostherapeutics.com. The Company encourages investors and potential investors to consult our website regularly for important information about iTeos.

Forward-Looking Statements

This press release contains forward-looking statements. Any statements that are not solely statements of historical fact are forward-looking statements. Words such as “believe,” “anticipate,” “plan,” “expect,” “will,” “may,” “intend,” “prepare,” “look,” “potential,” “possible” and similar expressions are intended to identify forward-looking statements. These forward-looking statements include statements relating to the potential benefits of inupadenant
and the adenosine gene signature; and iTeos remaining committed to focusing its resources on developing differentiated, first- or best-in-class therapies.

These forward-looking statements involve risks and uncertainties, many of which are beyond iTeos’ control. Actual results could materially differ from those stated or implied by these forward-looking statements as a result of such risks and uncertainties. Known risk factors include the following: success in preclinical testing and early clinical trials does not ensure that later clinical trials will be successful, and early results from a clinical trial do not necessarily predict final results; interim and early data may change as more patient data become available and are subject to audit and verification procedures; the data for our product candidates may not be sufficient for obtaining regulatory approval to move into later stage trials or to commercialize products; iTeos may not be able to execute on its business plans, including meeting its expected or planned regulatory milestones and timelines, research and clinical development plans, and bringing its product candidates to market, for various reasons, some of which may be outside of iTeos’ control, including possible limitations of company financial and other resources, manufacturing limitations that may not be anticipated or resolved for in a timely manner, negative developments in the field of immuno-oncology, and regulatory, court or agency decisions such as decisions by the United States Patent and Trademark Office with respect to patents that cover our product candidates; and those risks identified under the heading “Risk Factors” in iTeos’ Annual Report on Form 10-Q for the period ended September 30, 2024 filed with the Securities and Exchange Commission (SEC) as well as other SEC filings made by the Company which you are encouraged to review.

Any of the foregoing risks could materially and adversely affect iTeos’ business, results of operations and the trading price of iTeos’ common stock. We caution investors not to place undue reliance on the forward-looking statements contained in this press release. iTeos does not undertake any obligation to publicly update its forward-looking statements other than as required by law.

For further information, please contact:

Investor Contact:

Carl Mauch
iTeos Therapeutics, Inc.
[email protected]

Media Contact:

[email protected]